Safety and Tolerability of Initiating Sacubitril-Valsartan With Spironolactone During Hospitalization for Acute Decompensated Heart Failure
Journal of Pharmacy Practice · 2025
DOI: 10.1177/08971900241262382 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Pharmacy Practice, 2025. Verfasst von Alexander R Levine und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Hospital of Central Connecticut, New Britain, CT, USA. Hauptthemen laut MEDLINE: Aminobutyrates, Angiotensin Receptor Antagonists, Biphenyl Compounds, Drug Combinations. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Initiation of sacubitril-valsartan and mineralocorticoid receptor antagonists (MRA) during hospitalization for acute decompensated heart failure (ADHF) may be an ideal time to optimize guideline-directed medical therapy. However, there is limited research assessing the safety of combining these agents in the hospital.
Methods
This was a multi-center, retrospective, propensity-score matched cohort study performed at 7 acute-care hospitals within a large health care system. All adult patients admitted with ADHF between January 1, 2019 to December 31, 2021 who received sacubitril-valsartan with MRA (MRA group) or without MRA (non-MRA group) and had a left ventricular ejection fraction (LVEF) < 40% were included in the study.
Results
220 patients were screened during the study time frame with 179 meeting inclusion criteria. Following propensity-score matching, 50 patients in the MRA group were matched to 50 patients in the non-MRA group. The overall incidence of adverse drug reactions (ADRs) was 24% in the non-MRA group compared to 20% in the MRA group ( P = .629). There was a significantly greater incidence of hyperkalemia in the MRA group (0% vs 10%; P = .022). None of the patients in the non-MRA group were readmitted within 30 days due to an ADR compared to 6% in the MRA group ( P = .079).
Conclusion
The addition of spironolactone to sacubitril-valsartan in the hospital setting following stabilization of ADHF did not lead to a significantly greater incidence of overall ADRs, but patients were more likely to develop hyperkalemia and there was a numerically higher incidence of 30-day readmissions due to ADRs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Hospital of Central Connecticut, New Britain, CT, USA.
- Department of Pharmacy, MidState Medical Center, Meriden, CT, USA.
- Department of Pharmacy, Saint Vincent's Medical Center, Bridgeport, CT, USA.
ORCID-Profile: Alexander R Levine
Zitieren
APA
Levine, A. R., Sasiela, K., & Baker, M. (2025). Safety and Tolerability of Initiating Sacubitril-Valsartan With Spironolactone During Hospitalization for Acute Decompensated Heart Failure. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900241262382
Vancouver
Levine AR, Sasiela K, Baker M. Safety and Tolerability of Initiating Sacubitril-Valsartan With Spironolactone During Hospitalization for Acute Decompensated Heart Failure. Journal of Pharmacy Practice. 2025. doi:10.1177/08971900241262382
BibTeX
@article{Levine2025,
author = {Levine, Alexander R and Sasiela, Katarzyna and Baker, Mark},
title = {Safety and Tolerability of Initiating Sacubitril-Valsartan With Spironolactone During Hospitalization for Acute Decompensated Heart Failure},
journal = {Journal of Pharmacy Practice},
year = {2025},
doi = {10.1177/08971900241262382}
}
EUVIMED